Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Yu-Xin Wang, Feng-Lian Li, Li-Xin Du, Jun-Fang Liu, Li-Gang Huo, Shu-Qing Li & Bin Tian. (2021) The Co-Expression of Melanoma-Antigen Family a Proteins and New York Esophageal Squamous Cell Carcinoma-1 in Breast Cancer: A Pilot Study. Cancer Management and Research 13, pages 6123-6128.
Read now
Read now
Mehmet A.N. Sendur, Sercan Aksoy & Kadri Altundag. (2013) Cardiotoxicity of novel HER2-targeted therapies. Current Medical Research and Opinion 29:8, pages 1015-1024.
Read now
Read now
Baris Boyraz, Mehmet A.N. Sendur, Sercan Aksoy, Taner Babacan, Emir C. Roach, Muhammet C. Kizilarslanoglu, Ibrahim Petekkaya & Kadri Altundag. (2013) Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Current Medical Research and Opinion 29:4, pages 405-414.
Read now
Read now
Articles from other publishers (19)
Muhammad Mustafa Alhussein, Abir Mokbel, Tammy Cosman, Nazanin Aghel, Eric H. Yang, Som D. Mukherjee, Susan Dent, Peter M. Ellis, Sukhbinder Dhesy-Thind & Darryl P. Leong. (2021) Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis. CJC Open 3:11, pages 1372-1382.
Crossref
Crossref
Luo‐lan Gui, Li Li, Li‐hou Dong, Shen‐si Xiang, Jian‐ping Zhai, Zhi‐qiang Ge & Hai‐feng Song. (2020) Method development and validation of LC–MS/MS‐based assay for the simultaneous quantitation of trastuzumab and pertuzumab in cynomolgus monkey serum and its application in pharmacokinetic study. Biomedical Chromatography 34:12.
Crossref
Crossref
Sherry-Ann Brown, Jordan C. Ray & Joerg Herrmann. (2020) Precision Cardio-Oncology: a Systems-Based Perspective on Cardiotoxicity of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors. Journal of Cardiovascular Translational Research 13:3, pages 402-416.
Crossref
Crossref
Yan-cui Liu, Ying Ma, Ning An, Ping Sun, Ying Wang & Cheng Sun. (2019) Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer. Medicine 98:38, pages e17262.
Crossref
Crossref
Eline Meulenberg. 2018. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering.
Cheng Luo, Song Chen, Na Xu, Chi Wang, Wen bo Sai, Wei Zhao, Ying chun Li, Xiao jing Hu, Hong Tian, Xiang dong Gao & Wen bing Yao. (2017) Glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties. Scientific Reports 7:1.
Crossref
Crossref
Zexi Hu, Xiaobo Wan, Rui Hao, Heng Zhang, Li Li, Lin Li, Qiang Xie, Peng Wang, Yibo Gao, She Chen, Min Wei, Zhidong Luan, Aiqun Zhang, Niu Huang & Liang Chen. (2015) Phosphorylation of Mutationally Introduced Tyrosine in the Activation Loop of HER2 Confers Gain-of-Function Activity. PLOS ONE 10:4, pages e0123623.
Crossref
Crossref
DUQUN CHEN, YIFAN LI, ZHENGMING SU, ZUHU YU, WENSHUI YU, YUCHI LI, YAOTING GUI, SHANGQI YANG & YONGQING LAI. (2015) Identification of miR-125a-5p as a tumor suppressor of renal cell carcinoma, regulating cellular proliferation, migration and apoptosis. Molecular Medicine Reports 11:2, pages 1278-1283.
Crossref
Crossref
Mehmet AN Sendur, Sercan Aksoy & Kadri Altundag. (2015) Pertuzumab-induced cardiotoxicity: safety compared with trastuzumab. Future Oncology 11:1, pages 13-15.
Crossref
Crossref
Tasuku Matsuoka. (2015) Recent advances in the HER2 targeted therapy of gastric cancer. World Journal of Clinical Cases 3:1, pages 42.
Crossref
Crossref
Peter Hammarsten, Johanna Winther, Stina H. Rudolfsson, Jenny Häggström, Amar Karalija, Lars Egevad, Torvald Granfors & Christopher J. Fowler. (2014) ErbB2 Receptor Immunoreactivity in Prostate Cancer: Relationship to the Androgen Receptor, Disease Severity at Diagnosis and Disease Outcome. PLoS ONE 9:9, pages e105063.
Crossref
Crossref
Gaëlle Thomas, Thierry Chardès, Nadège Gaborit, Caroline Mollevi, Wilhem Leconet, Bruno Robert, Nina Radosevic-Robin, Frédérique Penault-Llorca, Céline Gongora, Pierre-Emmanuel Colombo, Yassamine Lazrek, Rui Bras-Goncalves, Ariel Savina, David Azria, Hervé Bazin, André Pèlegrin & Christel Larbouret. (2014) HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. Oncotarget 5:16, pages 7138-7148.
Crossref
Crossref
M. N. Macias, D. S. Shin, B. Ledezma & S. Sadeghi. (2014) Metastatic human epidermal growth factor 2 (HER2/neu) amplified breast cancer with acute fulminant hepatitis responding to trastuzumab, pertuzumab and carboplatin. Case Reports 2014:jun04 1, pages bcr2013203400-bcr2013203400.
Crossref
Crossref
Jinming Gu, Jinsong Yang, Qing Chang, Xiaoqing Lu, Jieyi Wang, Mingjiu Chen, Tariq Ghayur & Jijie Gu. (2014) Identification of Anti-ErbB2 Dual Variable Domain Immunoglobulin (DVD-Ig™) Proteins with Unique Activities. PLoS ONE 9:5, pages e97292.
Crossref
Crossref
Joseph J. MalyErin R. Macrae. (2014) Pertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival. Breast Cancer: Basic and Clinical Research 8, pages BCBCR.S9032.
Crossref
Crossref
Brian Godman, Alexander E Finlayson, Parneet K Cheema, Eva Zebedin-Brandl, Inaki Gutiérrez-Ibarluzea, Jan Jones, Rickard E Malmström, Elina Asola, Christoph Baumgärtel, Marion Bennie, Iain Bishop, Anna Bucsics, Stephen Campbell, Eduardo Diogene, Alessandra Ferrario, Jurij Fürst, Kristina Garuoliene, Miguel Gomes, Katharine Harris, Alan Haycox, Harald Herholz, Krystyna Hviding, Saira Jan, Marija Kalaba, Christina Kvalheim, Ott Laius, Sven-Ake Lööv, Kamila Malinowska, Andrew Martin, Laura McCullagh, Fredrik Nilsson, Ken Paterson, Ulrich Schwabe, Gisbert Selke, Catherine Sermet, Steven Simoens, Dominik Tomek, Vera Vlahovic-Palcevski, Luka Voncina, Magdalena Wladysiuk, Menno van Woerkom, Durhane Wong-Rieger, Corrine Zara, Raghib Ali & Lars L Gustafsson. (2013) Personalizing health care: feasibility and future implications. BMC Medicine 11:1.
Crossref
Crossref
Yao-Shan Fan. (2013) Companion Diagnostic Testing for Targeted Cancer Therapies: An Overview. Genetic Testing and Molecular Biomarkers 17:7, pages 515-523.
Crossref
Crossref
Iole Cucinotto, Lucia Fiorillo, Simona Gualtieri, Mariamena Arbitrio, Domenico Ciliberto, Nicoletta Staropoli, Anna Grimaldi, Amalia Luce, Pierfrancesco Tassone, Michele Caraglia & Pierosandro Tagliaferri. (2013) Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time?. Journal of Drug Delivery 2013, pages 1-10.
Crossref
Crossref
Lina Reslan & Charles Dumontet. 2013. Resistance to Immunotherapeutic Antibodies in Cancer. Resistance to Immunotherapeutic Antibodies in Cancer
1
24
.